Literature DB >> 22418887

Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications.

Patrick G Northup1, Curtis K Argo, Neeral Shah, Stephen H Caldwell.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disorders with a high prevalence in the industrialized world. Despite the high prevalence, the etiology and fundamental pathophysiology for the disease process is poorly understood. There is now a growing fund of knowledge suggesting that the ongoing inflammatory state associated with NAFLD leads to a low-level activation of the coagulation system. Although the data supporting this activation of the coagulation system are significant, the link with end-organ disease, mainly cardiovascular disease, is less firm and mostly epidemiological. In this review, we will explore the evidence for and against a hypercoagulable or thrombophilic state in NAFLD. We will examine possible pathophysiologic explanations and mechanisms, human epidemiologic and population-based data, and the possible therapeutic and preventative implications for treatment of thrombophilia in patients with this disease process. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418887     DOI: 10.1055/s-0032-1306425

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  14 in total

Review 1.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

2.  Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer.

Authors:  Aida Moeini; Hiroko Machida; Tsuyoshi Takiuchi; Erin A Blake; Marianne S Hom; Toshio Miki; Osamu Matsuo; Koji Matsuo
Journal:  Clin Appl Thromb Hemost       Date:  2016-08-31       Impact factor: 2.389

3.  Pre-transplant portal vein thrombosis is an independent risk factor for graft loss due to hepatic artery thrombosis in liver transplant recipients.

Authors:  Jonathan G Stine; Shawn J Pelletier; Timothy M Schmitt; Robert J Porte; Patrick G Northup
Journal:  HPB (Oxford)       Date:  2015-12-10       Impact factor: 3.647

Review 4.  Coagulopathy in liver disease: Lack of an assessment tool.

Authors:  Annabel Blasi
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 5.  Role of hemostatic factors in hepatic injury and disease: animal models de-liver.

Authors:  A K Kopec; N Joshi; J P Luyendyk
Journal:  J Thromb Haemost       Date:  2016-05-10       Impact factor: 5.824

Review 6.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

7.  New insights into NAFLD and subclinical coronary atherosclerosis.

Authors:  Lisa B VanWagner
Journal:  J Hepatol       Date:  2018-02-17       Impact factor: 25.083

Review 8.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

9.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28

Review 10.  Cardiovascular dysfunction in patients with liver cirrhosis.

Authors:  Giuseppe Fede; Graziella Privitera; Tania Tomaselli; Luisa Spadaro; Francesco Purrello
Journal:  Ann Gastroenterol       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.